Form 8-K - Current report
September 07 2023 - 5:01PM
Edgar (US Regulatory)
0000876343
false
0000876343
2023-09-06
2023-09-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 6, 2023
Lineage
Cell Therapeutics, Inc.
(Exact
name of Registrant as Specified in Its Charter)
California |
|
001-12830 |
|
94-3127919 |
(State
or Other Jurisdiction
of
Incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification
No.) |
2173
Salk Avenue, Suite 200
Carlsbad,
California
|
|
94-92008 |
(Address
of Principal Executive Offices) |
|
(Zip
Code) |
(442)
287-8990
Registrant’s
Telephone Number, Including Area Code
Not
Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
shares |
|
LCTX |
|
NYSE
American |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
As
described under Item 5.07 below, at the annual meeting of shareholders (the “Annual Meeting”) of Lineage
Cell Therapeutics, Inc. (the “Company”) held on September 6, 2023, the Company’s shareholders approved an amendment
(the “EIP Amendment”) to the Company’s 2021 Equity Incentive Plan (the “2021 Plan”), pursuant to which
the number of common shares of the Company available for issuance under the 2021 Plan was increased by 19,500,000. The Company’s
board of directors previously approved the EIP Amendment, subject to shareholder approval. A more complete description of the EIP Amendment
and a summary of the 2021 Plan, as amended by the EIP Amendment, is in the Company’s definitive proxy statement for the Annual
Meeting, which was filed with the U.S. Securities and Exchange Commission on July 27, 2023 (the “Proxy Statement”), and is
incorporated herein by reference. The foregoing summary of the EIP Amendment is qualified in its entirety by reference to the EIP Amendment,
a copy of which is filed as an exhibit to this report.
Item
5.07 Submission of Matters to a Vote of Security Holders.
The
Annual Meeting was held on September 6, 2023. The matters voted upon at the Annual Meeting are described in detail in the Proxy Statement.
Below is a brief description of each such matter and the final voting results, including the number of votes cast for, withheld or against,
the number of abstentions and the number of broker non-votes with respect to each matter, as applicable.
Proposal
1. The Company’s shareholders elected the nine nominees named below to the Company’s board of directors to hold office
until the Company’s 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified by
the following votes:
Nominee | |
Votes For | | |
Votes Withheld | | |
Broker Non-Votes | |
Dipti Amin | |
| 74,273,372 | | |
| 1,103,028 | | |
| 43,913,515 | |
Deborah Andrews | |
| 74,096,073 | | |
| 1,280,327 | | |
| 43,913,515 | |
Don Bailey | |
| 73,391,291 | | |
| 1,985,109 | | |
| 43,913,515 | |
Neal C. Bradsher | |
| 73,396,208 | | |
| 1,980,192 | | |
| 43,913,515 | |
Brian M. Culley | |
| 74,426,506 | | |
| 949,894 | | |
| 43,913,515 | |
Alfred D. Kingsley | |
| 71,157,090 | | |
| 4,219,310 | | |
| 43,913,515 | |
Anula Jayasuriya | |
| 73,404,130 | | |
| 1,972,270 | | |
| 43,913,515 | |
Michael H. Mulroy | |
| 63,115,746 | | |
| 12,260,654 | | |
| 43,913,515 | |
Angus C. Russell | |
| 55,755,116 | | |
| 19,621,284 | | |
| 43,913,515 | |
Proposal
2. The Company’s shareholders ratified the appointment of WithumSmith+Brown, PC as the Company’s independent registered
public accounting firm for the fiscal year ending December 31, 2023, by the votes set forth below.
Votes For | | |
Vote Against | | |
Abstentions | | |
Broker Non-Votes | |
| 118,493,370 | | |
| 481,961 | | |
| 314,584 | | |
| — | |
Proposal
3. The Company’s shareholders approved, on an advisory and non-binding basis, the compensation paid to the Company’s
named executive officers, as set forth in the Proxy Statement, by the votes set forth below.
Votes For | | |
Vote Against | | |
Abstentions | | |
Broker Non-Votes | |
| 70,271,698 | | |
| 4,542,895 | | |
| 561,807 | | |
| 43,913,515 | |
Proposal
4. The Company’s shareholders voted as follows with respect to the preferred frequency of holding an advisory vote on the compensation
of the Company’s named executive officers.
Every Year | | |
Every Two Years | | |
Every Three Years | | |
Abstentions | | |
Broker Non-Votes | |
| 71,622,410 | | |
| 983,734 | | |
| 975,224 | | |
| 1,795,032 | | |
| 43,913,515 | |
Proposal
5. The Company’s shareholders approved the EIP Amendment by the votes set forth below.
Votes For | | |
Vote Against | | |
Abstentions | | |
Broker Non-Votes | |
| 66,175,977 | | |
| 8,543,323 | | |
| 657,100 | | |
| 43,913,515 | |
Proposal
6. The Company’s shareholders approved an amendment to the Company’s restated articles of incorporation to increase the
number of authorized common shares from 250,000,000 to 450,000,000 by the votes set forth below.
Votes For | | |
Vote Against | | |
Abstentions | | |
Broker Non-Votes | |
| 108,314,123 | | |
| 10,203,002 | | |
| 772,790 | | |
| — | |
Proposal
7. The Company’s shareholders approved the adjournment of the Annual Meeting, if necessary or advisable, to solicit additional
proxies in favor of Proposal 6 in the event there are not sufficient votes to approve Proposal 6 by the votes set forth below.
Votes For | | |
Vote Against | | |
Abstentions | | |
Broker Non-Votes | |
| 108,130,223 | | |
| 10,087,729 | | |
| 1,071,963 | | |
| — | |
In
light of the results on proposal 4, and consistent with the board of directors’ recommendation, the Company will include the shareholder
advisory vote on named executive officer compensation in its proxy materials every year until the next required vote on the frequency
of shareholder advisory votes on executive compensation.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
*
Incorporated by reference from Appendix A to the Proxy Statement.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Lineage
Cell Therapeutics, Inc. |
|
|
|
Date:
September 7, 2023 |
By: |
/s/
George A. Samuel III |
|
|
George
A. Samuel III |
|
|
General
Counsel and Corporate Secretary |
v3.23.2
Cover
|
Sep. 06, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Sep. 06, 2023
|
Entity File Number |
001-12830
|
Entity Registrant Name |
Lineage
Cell Therapeutics, Inc.
|
Entity Central Index Key |
0000876343
|
Entity Tax Identification Number |
94-3127919
|
Entity Incorporation, State or Country Code |
CA
|
Entity Address, Address Line One |
2173
Salk Avenue
|
Entity Address, Address Line Two |
Suite 200
|
Entity Address, City or Town |
Carlsbad
|
Entity Address, State or Province |
CA
|
Entity Address, Postal Zip Code |
94-92008
|
City Area Code |
(442)
|
Local Phone Number |
287-8990
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
shares
|
Trading Symbol |
LCTX
|
Security Exchange Name |
NYSEAMER
|
Entity Emerging Growth Company |
false
|
Entity Information, Former Legal or Registered Name |
Not
Applicable
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Apr 2024 to May 2024
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From May 2023 to May 2024